| Field | Specification |
|---|---|
| Target | |
| Alternative names | ARQ-092 hydrochloride |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C27H25ClN6 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric inhibitor of Akt, with IC50 values of 2.7 nM for Akt1, 14 nM for Akt2 and 8.1 nM for Akt3. It also potently inhibits the AKT1-E17K mutant protein and has been proposed for research into PI3K/AKT-driven tumors and Proteus syndrome[1], and it is effective against Leishmania[2]. It is supplied as a light yellow to brown solid (C27H25ClN6, MW 468.98) at 99.74% purity.
Physical & Chemical Properties
| CAS Number | 1313883-00-9 |
|---|---|
| Molecular Formula | C27H25ClN6 |
| Molecular Weight | 468.98 g/mol |
| Purity | 99.74% |
| Appearance | Solid |
| Color | Light yellow to brown |
| SMILES | NC1=NC=CC=C1C2=NC3=CC=C(C4=CC=CC=C4)N=C3N2C5=CC=C(C6(N)CCC6)C=C5.[H]Cl |
| Target | Akt1, Leishmania, Akt3, Akt2, Akt1 E17K mutant |
| Signaling Pathway | PI3K/Akt/mTOR; Anti-infection |
| Solubility | In Vitro: DMSO: 50 mg/mL (106.61 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
[1][2]
|
Akt1 2.7 nM (IC50) |
Akt3 8.1 nM (IC50) |
Akt2 174 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 50 mg/mL (106.61 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL (5.33 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Data provided by the manufacturer.
In Vitro
Miransertib (ARQ-092; Compound 21a) shows potent anti-proliferative activity across a large panel of cell lines derived from various tumor types, in lines containing PIK3CA/PIK3R1 mutations relative to those with wild-type (wt) PIK3CA/PIK3R1 or PTEN loss. Excellent inhibition of p-Akt (S473) and p-Akt (T308) by Miransertib is seen in both AN3CA and A2780 cells. Miransertib (IC50=0.31 μM) inhibits the downstream protein p-PRAS40 (T246)[1]. Against intracellular amastigotes of L. donovani or L. amazonensis-infected macrophages, Miransertib is markedly effective. mTOR dependent autophagy in Leishmania-infected macrophages is also enhanced by Miransertib[2]
In Vivo
Good absolute oral bioavailability is shown by Miransertib (ARQ-092; Compound 21a) in rats (5 mg/kg) and monkeys (10 mg/kg), with F values of 62% and 49%, respectively. Half-life is longer in rats than in monkeys, with t1/2 values of 17 h in rats versus 7 h in monkeys. In rats and monkeys, respectively, Cmax is 198 ng/mL and 258 ng/mL, and AUCinf was 5496 h•ng/mL and 2960 h•ng/mL[1]. Tumor growth in a human xenograft mouse model of endometrial adenocarcinoma is inhibited by Miransertib (ARQ-092; Compound 21a)[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Targeted therapy for capillary-venous malformations. Signal Transduct Target Ther 2024 Jun 17;9(1):146. PMID: 38880808
Exosomal Oleic Acid Promotes Lymphangiogenesis and Nodal Metastasis in Cervical Cancer via the AKT/mTOR Pathway. J Extracell Vesicles 2026 Jun;15(6):e70328. PMID: 42338019
IGF1R-phosphorylated PYCR1 facilitates ELK4 transcriptional activity and sustains tumor growth under hypoxia. Nat Commun 2023 Sep 30;14(1):6117. PMID: 37777542
Paeoniflorin alleviates anxiety-like behaviors in sleep-deprived male mice by suppressing inflammation of the paraventricular nucleus of the hypothalamus. Phytomedicine 2026 Jun:155:158111. PMID: 41931995
Dysregulation of Rho-Associated Coiled-Coil Protein Kinase1 Depletes Neural Stem Cell Pool and Impairs Hippocampal Neurogenesis After Traumatic Brain Injury. Cell Prolif 2025 Aug 1:e70093. PMID: 40749978
Hesperetin alleviates aflatoxin B1 induced liver toxicity in mice: Modulating lipid peroxidation and ferritin autophagy. Ecotoxicol Environ Saf 2024 Oct 1:284:116854. PMID: 39142113
ED-71 Improves Bone Mass in Ovariectomized Rats by Inhibiting Osteoclastogenesis Through EphrinB2-EphB4-RANKL/OPG Axis. Drug Des Devel Ther 2024 May 6:18:1515-1528. PMID: 38716369
Hyperglycemia-Reduced Platelet-Derived Growth Factor-BB Expression Impairs Corneal Wound Healing in Diabetic Mice. Invest Ophthalmol Vis Sci 2025 Aug 1;66(11):61. PMID: 40856651
Lipid Nanoparticle Delivery of iMDK Induces ATF3-Mediated Apoptosis in Sotorasib-Resistant KRAS Mutant Lung Cancer. Mol Pharm 2025 Sep 1;22(9):5523-5532. PMID: 40758603
Mechanistic, functional and clinical aspects of pro-inflammatory cytokine mediated regulation of ADME gene expression in 3D human liver spheroids. Clin Pharmacol Ther 2023 Sep;114(3):673-685. PMID: 37307233
